In a decision that has ignited fierce debate, Susan Monarez, PhD, Acting Director of the U.S. Centers for Disease Control and Prevention (CDC), recently endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation to vaccinate children aged 5-11 against COVID-19 with the Pfizer-BioNTech pediatric vaccine. Announced in late 2021 and reinforced through ongoing CDC guidance, this move extends vaccine recommendations to over 28 million children nationwide, authorizing providers to begin administering the shots. At first glance, it might seem like a standard public health strategy to combat a global pandemic. Yet, a deeper dive reveals a troubling rift between this policy and the scientific evidence—a rift that Monarez and the ACIP appear to have overlooked, potentially undermining the very mission they are sworn to uphold.

The ACIP, a committee within the CDC, is charged with providing evidence-based guidance on vaccine use to prevent diseases in the civilian population. Its mission is to develop recommendations for vaccine administration, schedules, and safety grounded in rigorous data, as outlined on the CDC’s ACIP overview page. Critics, however, contend that Monarez’s endorsement of the pediatric COVID-19 vaccine betrays this mandate. Far from preventing disease or transmission, the COVID-19 vaccines—often labeled experimental gene therapies—have failed to live up to their initial hype, as evidenced by peer-reviewed studies, legal rulings, and even admissions from figures like Dr. Anthony Fauci and Peter Marks, MD, PhD, Director of FDA Vaccine Division. This article explores the evidence, drawing heavily from the report COUNTERMEASURE “VACCINE” – NOT EFFECTIVE, NOT SAFE, NOT MADE AT “WARP SPEED”, to argue that the CDC’s push to vaccinate young children is a profound breach of public trust.

The Illusion of Efficacy: Vaccines That Don’t Stop the Virus

When the COVID-19 vaccines debuted, they were celebrated as a scientific breakthrough, promising to halt SARS-CoV-2 and restore normalcy. The Pfizer-BioNTech vaccine, in particular, boasted over 90% efficacy against symptomatic infection in early clinical trials, as detailed in Pfizer’s press release. But as real-world data rolled in, a starkly different story emerged—one that Monarez and the ACIP have conspicuously ignored.

Dr. Anthony Fauci, a linchpin of the U.S. pandemic response, has inadvertently spotlighted this failure. On August 13, 2024, he disclosed contracting COVID-19 for the third time, despite being vaccinated and boosted six times, as captured in a Twitter video. This wasn’t a fluke but a symptom of a wider trend: vaccinated individuals, even those with multiple doses, continue to contract and spread the virus. Fauci reinforced this in a July 12, 2022, interview, admitting that “vaccines do not protect overly well against infection,” as seen in a Rumble clip.  And on April 6, 2022, Peter Marks, MD, PhD, Director of FDA Vaccine Division, admits boosters are ineffective at preventing infection but continues to support this strategy as a temporary “stopgap measure” — “until a proper solution is found.”   Then on May 22, 2022 Dr Marks testified to Congress: Youngest kids vaccine won’t need to hit 50% efficacy mark. Two doses of pediatric vaccine failed to trigger an immune response in 2-, 3- and 4-year-olds.” (Marks was forced to resign on March 28, 2025 or get fired).

If the vaccines falter in adults like Fauci, and in children as per Marks’ own admissions, what rationale justifies exposing children—who face negligible risk from COVID-19—to the same intervention? 

The judiciary has echoed this sentiment. On June 7, 2024, the United States Court of Appeals for the Ninth Circuit ruled in Health Freedom Defense Fund v. Carvalho that, unlike traditional vaccines, the COVID-19 shots do not prevent infection or transmission, as documented in the court’s decision. This ruling highlights a key distinction: while vaccines for smallpox or polio offer sterilizing immunity, stopping both disease and spread, the mRNA-based COVID-19 vaccines do not. This legal finding aligns with a January 11, 2023, paper co-authored by Fauci in Cell Host & Microbe, which conceded that SARS-CoV-2 and other respiratory viruses “have not to date been effectively controlled by licensed or experimental vaccines,” available in PDF format.

Pfizer’s Admissions and the FDA’s Role

If the vaccines don’t halt the virus, why are they being injected into children? The answer grows murkier with revelations from Pfizer itself. On January 19, 2024, Pfizer admitted in federal court that its COVID-19 gene therapies—commonly marketed as vaccines—were never approved by the U.S. Food and Drug Administration (FDA), operating instead under Emergency Use Authorization (EUA), a lesser standard lacking long-term safety data, as noted in a federal court filing. This admission casts doubt on the CDC’s decision to target children, a group already at minimal risk from severe COVID-19 outcomes.

CDC data underscores this low risk: children aged 5-11 have a survival rate exceeding 99.99%, with severe cases largely confined to those with significant comorbidities, per the CDC COVID Data Tracker. Yet, Monarez and the ACIP press on, undeterred by the vaccines’ inability to prevent disease and prevent transmission or their EUA status. This disconnect fuels suspicions that the CDC prioritizes pharmaceutical profits over public health—a theory bolstered by Pfizer’s staggering $100 billion-plus revenue from its COVID-19 vaccine by 2023, according to Statista.

Safety Concerns: Uncharted Territory for Kids

Beyond efficacy, the safety of the Pfizer-BioNTech pediatric vaccine remains contentious. The COUNTERMEASURE “VACCINE” report cites peer-reviewed studies and adverse event data suggesting significant risks, especially for younger populations. Myocarditis and pericarditis—heart inflammation conditions—have emerged as notable side effects, particularly in young males post-mRNA vaccination. A 2022 study in JAMA reported a heightened risk of myocarditis within 21 days of vaccination, with rates as high as 1 in 2,650 for males aged 12-17, detailed in the JAMA article. Though the pediatric dose for 5-11-year-olds is lower (10 micrograms versus 30 micrograms), long-term data are absent, thanks to the rushed trials of Operation Warp Speed.

Here are some key safety concerns raised by critics:

• Myocarditis and Pericarditis Risk: Elevated incidence in young males, potentially leading to permanent heart damage.

• Underreported Adverse Events: Whistleblower testimony from U.S. Senate hearings suggests VAERS data may underrepresent harms, as cited on Senator Ron Johnson’s website.

• Unknown Long-Term Effects: No comprehensive studies exist on the impact of mRNA vaccines in children over decades.

• Disproportionate Risk: Children face minimal COVID-19 threat, amplifying the relative danger of vaccine side effects.

The CDC acknowledges these risks but minimizes them, claiming benefits outweigh dangers, per its myocarditis guidance. Critics argue this logic collapses for children, who rarely suffer severe COVID-19 but could face lasting vaccine-related harm.

A Mission Abandoned?

The ACIP’s core mission is to safeguard the public with safe, effective, and necessary vaccines. Monarez’s endorsement of the pediatric COVID-19 vaccine seems to forsake this duty. If the shots don’t prevent infection or transmission—as Fauci, Marks, the Ninth Circuit, and Pfizer concede—their public health value is dubious. For children, the case disintegrates: the disease poses little threat, the vaccine offers no clear benefit, and the risks introduce unwarranted uncertainty into young lives.

This suggests a darker possibility: the CDC’s stance may reflect political or economic pressures rather than science. The EUA reliance and Pfizer’s court admissions mirror patterns of regulatory capture, where corporate influence shapes policy, as explored in an AMA Journal of Ethics analysis. With 28 million children now targeted, the implications are staggering.

Conclusion: A Call for Accountability

Susan Monarez’s backing of the ACIP’s recommendation isn’t merely a misstep—it’s a potential violation of the trust vested in the CDC to protect America’s children. The evidence is unequivocal: the Pfizer-BioNTech vaccine doesn’t meet traditional vaccine standards, and its use in a low-risk population defies the ACIP’s own principles. As parents, lawmakers, and citizens confront this reality, one question looms: how many more admissions, rulings, and studies will it take for the CDC to reconsider? Until then, the push to vaccinate 5-11-year-olds serves as a grim reminder that even revered institutions can drift from their mission when science yields to agenda.

Dr. Charles B. Simone argues that children should not receive the COVID-19 vaccine, emphasizing the principle of “above all, do no harm (CHILDREN SHOULD NOT GET THE “VACCINE” “ABOVE ALL DO NO HARM). He contends that children have a robust innate immunity and very few ACE2 receptors, which the SARS-CoV-2 virus requires to infect cells, resulting in a low risk of infection, illness, transmission, and mortality. Simone cites data suggesting that children rarely get infected or become ill, 99.995% survive a COVID infection, and highlights potential vaccine risks like myocarditis, which he claims has a high mortality rate in children. He questions the necessity of vaccinating children, pointing to natural immunity from prior exposure and the lack of evidence showing significant transmission from children to adults, urging a reevaluation of vaccination policies to prioritize safety and avoid unnecessary harm. He questions the necessity of vaccinating children, pointing to natural immunity from prior common cold coronavirus exposure, and even President Trump acknowledges that children have a strong immune system – “Leave our children alone”.

“Leave our children alone!” President Trump at the Arizona Republican Political Rally on January 15th, 2022

This article can also be found at https://forum.worldhealth.net/articles/the-cdcs-vaccine-push-for-children-a-betrayal-of-science-and-trust/

© 2025 C. B. Simone, M.MS., M.D.